Study of AK112 for lung cancer after targeted therapy failure
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new immunotherapy drug, AK112, for people with a specific type of lung cancer (non-squamous) that has certain genetic changes and has stopped responding to targeted therapy. The goal is to see if AK112 can help when targeted treatments no longer work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have advanced non-squamous lung cancer that has spread or cannot be surgically removed.
- Your cancer must have a specific genetic change (like EGFR, ALK, or others) and you must have already tried a targeted therapy that stopped working.
- You must be able to perform daily activities (ECOG score 0 or 1) and have a life expectancy of at least 3 months.
- You must not have received immunotherapy before.
- You must have at least one tumor outside the brain that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ABSK112 for people with advanced non-small cell lung cancer, especially those whose cancer has a specific change in the EGFR gene (exon 20 insertion). The main goals are to see if it's safe and how the body handles it.
This trial tests an experimental drug called AK138D1, either by itself or combined with another drug (ivonescimab), for people with advanced non-small cell lung cancer that has spread. It aims to see if these treatments are safe and effective.
This trial tests a combination of two new drugs (SHR-A1811 and AK112) for people with a specific type of advanced lung cancer that has changes in the HER2 gene. It may help those whose cancer has gotten worse after one previous treatment, or who have not yet had any treatment for advanced disease.
This trial studies AK104 along with chemotherapy given before surgery and after surgery for people with resectable (operable) stage II to IIIA non-small cell lung cancer. It aims to improve treatment effectiveness by shrinking the tumor before surgery and helping prevent it from coming back afterward.
This trial tests a combination of two experimental drugs, AK146D1 and AK112, for people with advanced non-small cell lung cancer that cannot be removed by surgery or treated with standard chemo-radiation. It aims to find out if this combination can shrink tumors or slow cancer growth.
This trial tests a new drug, AK112, combined with chemotherapy for people with non-squamous non-small cell lung cancer that has spread to the brain and does not have certain genetic changes. The goal is to see if this combination is safe and effective as the first treatment.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.